GCG and metabolic dysfunction-associated steatotic liver disease: Similarly, Nestor et al. compared ALT-801 (another dual GLP-1/GCG receptor agonist), semaglutide and elafibranor in AMLN diet NAFLD mouse model to validate the beneficial effects of GLP-1/GCG dual agonism in NAFLD hepatic outcomes.